Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina. Show more

Location: 4020 Stirrup Creek Drive, Durham, NC, 27703, United States | Website: https://pelthos.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

84.57M

52 Wk Range

$4.50 - $54.29

Previous Close

$27.80

Open

$28.62

Volume

25,268

Day Range

$27.82 - $32.00

Enterprise Value

86.82M

Cash

59.17K

Avg Qtr Burn

-481.9K

Insider Ownership

64.20%

Institutional Own.

10.43%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date